Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 5/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3250637 | 0.95 | FDFT1 (0.39) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL3249343 | 0.94 | PTGER1 (0.39) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL3244429 | 0.90 | PTGER1 (0.42) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL14107543 | 0.89 | THRB (0.42) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL5456178 | 0.89 | FDFT1 (0.40) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL13357732 | 0.89 | KEAP1 (0.39) | FDFT1THRBALDH1A1POLBLMNA | |
| SCHEMBL3256139 | 0.88 | PTGER1 (0.44) | FDFT1THRBALDH1A1POLBPTGER1 | |
| SCHEMBL14107573 | 0.86 | POLB (0.38) | THRBALDH1A1POLBLMNAPTGER1 | |
| SCHEMBL3253932 | 0.86 | HPGD (0.34) | THRBALDH1A1LMNAEPHX2HPGD | |
| SCHEMBL13357749 | 0.85 | THRB (0.36) | FDFT1THRBALDH1A1POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-7396958-B2 | Sulphonamide derivatives, their preparation and their therapeutic application | SANOFI AVENTIS (FR) | 2008-07-08 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185136-A1 | SULPHONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | HCRTR2, GIPR, SSTR2 | FDFT1 1608/4885THRB 84/4885ALDH1A1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.